Compare Broadcom Inc (AVGO) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs CVS Health Corp — how do they compare? Broadcom Inc trades at $418.39 (market cap $2.01T), while CVS Health Corp trades at $93.7 (market cap $122.36B). The key difference: Broadcom Inc is far larger — about 16.4× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| AVGO | CVS | |
|---|---|---|
Market Cap | $2.01T | $122.36B |
Sector | Technology | Health |
52-Week High | $481.57 | $110.60 |
52-Week Low | $289.60 | $65.51 |
Enterprise Value | $2.05T | $184.71B |
Dividend Yield | 0.62% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $427.76, up 1.71% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust earnings beats, with Q1 2026 EPS of $2.44 exceeding expectations, and AI semiconductor revenue surged 143% year-over-year to $10.8 billion in Q2 2026. Valuation ratios are elevated, with a P/E of 71.17, reflecting high growth expectations.
Outlook remains positive driven by AI demand, with CEO Hock Tan forecasting over $100 billion in AI semiconductor revenue by 2027. Risks include competitive pressures and high debt levels. Analysts are overwhelmingly bullish, with a consensus price target of $510.21, implying 19% upside from current levels.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
